Since stem cell therapy is the most effective treatment in the field of tissue reparation and reconstitution,the present study aimed to explore the different sources of mesenchymal stem cells(MSCs)on the different eff...Since stem cell therapy is the most effective treatment in the field of tissue reparation and reconstitution,the present study aimed to explore the different sources of mesenchymal stem cells(MSCs)on the different effects of pulmonary fibrosis-related cytokines in C57BL/6 mice.For reaching this goal,we isolated MSCs from umbilical cord blood and placenta and used for stem cell therapy in a mouse model of pulmonary fibrosis model.The pulmonary fibrosis model was done by injecting bleomycin into the trachea of C57BL/6 mice.Then we assessed the degree of pulmonary fibrosis in each mouse lung tissue at weeks 1,2,3,and 4.In addition,flow cytometry was used to evaluate the frequency of CD73,CD90,CD106,CD34,CD45,CD14 cells at the mononuclear cell level;and western blotting assays revealed the expression of IκB-α.Our results showed that stem cell therapy by placenta-derived MSC had a lower level of CD34,CD45,CD14 cells at the mononuclear cell level,and that improved pulmonary fibrosis at both molecular and pathological levels.In addition,western blotting assays revealed that the expression of IκB-αwas down-regulated in MSC-treated animals.In addition,placenta-derived MSC was the most effective in improving pulmonary fibrosis in comparison to other sources.This study suggests that MSC might be a novel therapeutic approach in pulmonary fibrosis due to an enhanced anti-inflammatory effect.Also,MSC modification by gene editing could enhance their therapeutic effect in mouse pulmonary fibrosis.展开更多
基金This work was financially supported by the National Natural Science Foundation of China(31001638&30870602)This project was supported by the key medical research plan of the Hebei province of China(No.ZD2013063)+1 种基金Tsing-hua University(2009THZ02122)National Heart,Lung,and Blood Institute Research Grant HL 104402 from the National Institutes of Health of the US Public Health Service.
文摘Since stem cell therapy is the most effective treatment in the field of tissue reparation and reconstitution,the present study aimed to explore the different sources of mesenchymal stem cells(MSCs)on the different effects of pulmonary fibrosis-related cytokines in C57BL/6 mice.For reaching this goal,we isolated MSCs from umbilical cord blood and placenta and used for stem cell therapy in a mouse model of pulmonary fibrosis model.The pulmonary fibrosis model was done by injecting bleomycin into the trachea of C57BL/6 mice.Then we assessed the degree of pulmonary fibrosis in each mouse lung tissue at weeks 1,2,3,and 4.In addition,flow cytometry was used to evaluate the frequency of CD73,CD90,CD106,CD34,CD45,CD14 cells at the mononuclear cell level;and western blotting assays revealed the expression of IκB-α.Our results showed that stem cell therapy by placenta-derived MSC had a lower level of CD34,CD45,CD14 cells at the mononuclear cell level,and that improved pulmonary fibrosis at both molecular and pathological levels.In addition,western blotting assays revealed that the expression of IκB-αwas down-regulated in MSC-treated animals.In addition,placenta-derived MSC was the most effective in improving pulmonary fibrosis in comparison to other sources.This study suggests that MSC might be a novel therapeutic approach in pulmonary fibrosis due to an enhanced anti-inflammatory effect.Also,MSC modification by gene editing could enhance their therapeutic effect in mouse pulmonary fibrosis.
